Karina Segovia

Contact Information	• Av Medrano 134 floor 6 Caba. Bs As. Argentina. Zip Codel C1179AAB. • phone 054 011 4983 1589. • Email: karinasegovia@imoba.com.ar
Education	• Laboratory technician, Argentine Red Cross. Bs As 2011 • Provision 6677/10 ANMAT, Imoba 2017 • ANMAT 6677/2010, LATAM Jun 2019 • Good clinical practices, Eli Lilly 2017. (last current update) • IATA Mayo Clinic standards, 2019. • IATA Mayo Clinic standards, Oct 2021. • Good Clinical Practice, The Global Healt Network, Oct 2021. • Diploma in Good Practices in Biomedical Research. University of San Pablo.Tucumán. August 2020 to July 2021 (238 hours).
Current employment information	• Investigaciones Médicas IMOBA SRL • Av Medrano 134 floor 6 CABA • Laboratory technician from December 2017 to the present.
License	• N 118228
	➢ I8B-MC-ITRN Prospective, double-blind, randomized study of LY900014 compared with insulin Lispro in combination with insulin Glargine or insulin

Clinical studies in the last 5 years	Degludec in adults with type 2 diabetes PRONTO-T2D. From 2018 to 2019. Phase III. Eli Lilly. Studies coordinator. ➢ I8B-MC-ITRM Prospective, double-blind, randomized study of LY900014 compared with Lispro insulin with an open-label treatment group with postprandial LY900014 in combination with insulin Glargine or insulin Degludec in adults with type 1 diabetes PRONTO-T1D. From 2018 to 2019. Phase III. Eli Lilly. ➢ CLCZ696D2301 Multicenter, randomized, double-blind, parallel-group, active-controlled study to evaluate the efficacy and safety of LCZ696, compared to valsartan, on morbidity and mortality in participants with heart failure (Class II-IV of NYHA) and preserved ejection fraction. From 2018 to the present. Phase 3. Novartis. ➢ LIK066 Multicenter, randomized, double-blind, parallel-group, dose-finding study to evaluate the effect of 3 doses of LIK066 compared to placebo or empagliflozin in patients with type 2 diabetes mellitus with heart failure. From 2018 to 2018. Phase III. Novartis.
Estudios Clínicos realizados en los últimos 5 años.	➢ EFC14828 –AMPLITUDE-O - Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of efpeglenatide on cardiovascular outcomes in patients with type 2 diabetes who are at high risk for cardiovascular disease. Sanofi Aventis. Phase III. From 2018 to Jun 2021. ➢ EFC14875- SCORED: Multicenter, randomized, double-blind, placebo-controlled study in parallel groups, to demonstrate the effects of zotagliphozin on cardiovascular and renal events in patients with type II diabetes, cardiovascular risk factors and moderate renal failure. Phase III. Sanofi Aventis. From 2018 to April 2021. ➢ 1002-043 (CLEAR), entitled “Randomized, double-blind, placebo-controlled study to evaluate the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with cardiovascular disease or at high risk of developing it, they do not tolerate statins ”. Phase III. Clixar. From 2018 to the present. ➢ Protocol H9X-MC-GBGL "A randomized, double-blind, parallel-arm study to study the efficacy and safety of investigational doses of Dulaglutide when added to Metformin in patients with type 2 diabetes mellitus." From 2018 to December 2019. Phase III. Eli Lilly.

	➢ K-877-302 Prominent Pemafibrate to reduce cardiovascular outcomes by lowering triglycerides in patients with diabetes. From 2018 to the present. Phase III. Quintiles. ➢ I8F-MC-GPGM Efficacy and safety of Ly3298176 once a week vs insulin glargine in patients with type 2 diabetes and high cardiovascular risk. From March 2018 to July 2021. Phase III. Eli Lilly. ➢ I8F-MC-GPGH: Phase 3 open-label, randomized study comparing the effect of LY3298176 vs titrated insulin Degludec on the glycemic control of pts. with type 2 diabetes. Eli Lilly. From July 2018 to April 2021. Phase III. Eli Lilly. ➢ I8F-MC-GPGL: Randomized, open-label, phase 3 trial, comparing the efficiency and safety of Tirzepatide vs Semaglutide once a week as an add-on therapy to metformin in patients with type 2 DBT. Eli Lilly. From July 2019 to May 2021. Phase III. Eli Lilly. ➢ FINEART s-HF-(Bayer) Multicenter, randomized, double-blind, placebo-controlled parallel group study to evaluate the efficacy and safety of finerenone in morbidity and mortality in patients with Heart Failure (NYHA II-IV) and fraction left ventricular ejection >=40% (LVEF >=40%). Phase 3. Lab. Technician. From Oct 2020 to present. ➢ I8H-MC-BDCL A Phase 2 parallel, camparator- Controlled Trial to Evaluate the Safefty and Efficacy of LY3209590 in Insulin- Native with Type 2 Diabetes Mellitus. Eli Lilly.From Nov 2020 to present. ➢ I8F-MC-GPHM Efficacy and SAfefty of Tirzepatide Once Weekly vs Placebo after an intensive Lifestyle Program participants without Type 2 Diabetes who have Obesiy or are Overweight with weight- related Comorbidities: Randomized Double Blind, Placebo Controlled Trial. From April 2021 to present. ➢ I8F-MC-GPHD Arandomized, phase 3, open label Trial comparing the effect of the addition of tirzepatide once weekly vs insulin lispro (U100)Three times daily in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin. From Dec 2020 to present.

Signature: Date: